source
- Amgen defends Tavneos as FDA, European regulators and Japanese doctors raise safety concernsAmgen said it continues to support its rare-disease therapy Tavneos despite recent safety alerts. The U.S. FDA has indicated it wants the drug removed from the market after a report of 20 deaths l…
- Merck and Kelun-Biotech's ADC sac-TMT secures first global Phase 3 win ahead of scheduleMerck and China-based Kelun-Biotech reported that their experimental antibody-drug conjugate sac-TMT achieved a positive outcome in a global Phase 3 study, marking the first such success for the ca…